Sarra El-Abed

559 total citations
15 papers, 59 citations indexed

About

Sarra El-Abed is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sarra El-Abed has authored 15 papers receiving a total of 59 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sarra El-Abed's work include HER2/EGFR in Cancer Research (8 papers), Breast Cancer Treatment Studies (5 papers) and Advanced Breast Cancer Therapies (4 papers). Sarra El-Abed is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Breast Cancer Treatment Studies (5 papers) and Advanced Breast Cancer Therapies (4 papers). Sarra El-Abed collaborates with scholars based in Belgium, Switzerland and Italy. Sarra El-Abed's co-authors include Martine Piccart, Serena Di Cosimo, Alvaro Moreno‐Aspitia, Noam Pondé, Saranya Chumsri, Richard D. Gelber, Evandro de Azambuja, Giuseppe Viale, Judith M. Bliss and Fausto Petrelli and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Sarra El-Abed

13 papers receiving 58 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarra El-Abed Belgium 5 43 30 15 14 4 15 59
José Rodrigo Espinosa Fernández United States 5 44 1.0× 26 0.9× 17 1.1× 10 0.7× 4 1.0× 9 68
Annette Kolodzie United States 4 35 0.8× 22 0.7× 17 1.1× 20 1.4× 5 1.3× 6 58
Audrey Gill United States 3 24 0.6× 23 0.8× 19 1.3× 19 1.4× 2 0.5× 4 43
Vesna Glavicic Denmark 5 33 0.8× 21 0.7× 8 0.5× 20 1.4× 6 1.5× 11 50
John Devar South Africa 7 56 1.3× 16 0.5× 37 2.5× 11 0.8× 3 0.8× 18 91
Mariane Fontes United Kingdom 2 32 0.7× 25 0.8× 37 2.5× 17 1.2× 2 0.5× 4 61
Sarah Kernaghan United Kingdom 4 34 0.8× 30 1.0× 11 0.7× 23 1.6× 4 1.0× 10 52
A.A. Luczak Denmark 4 38 0.9× 11 0.4× 6 0.4× 18 1.3× 3 0.8× 11 45
Brian Chirn United States 3 31 0.7× 39 1.3× 36 2.4× 15 1.1× 2 0.5× 4 75
Melissa Choz United States 3 36 0.8× 36 1.2× 11 0.7× 10 0.7× 1 0.3× 3 53

Countries citing papers authored by Sarra El-Abed

Since Specialization
Citations

This map shows the geographic impact of Sarra El-Abed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarra El-Abed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarra El-Abed more than expected).

Fields of papers citing papers by Sarra El-Abed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarra El-Abed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarra El-Abed. The network helps show where Sarra El-Abed may publish in the future.

Co-authorship network of co-authors of Sarra El-Abed

This figure shows the co-authorship network connecting the top 25 collaborators of Sarra El-Abed. A scholar is included among the top collaborators of Sarra El-Abed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarra El-Abed. Sarra El-Abed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
El-Abed, Sarra, et al.. (2025). Integrated experimental and computational analysis reveals amoxicillin binding dynamics to PBP1a in Staphylococcus aureus. Scientific Reports. 15(1). 20284–20284. 2 indexed citations
2.
3.
Demeestere, Isabelle, Samuel M. Niman, AH Partridge, et al.. (2025). 415O Predictive factors of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in the POSITIVE trial. ESMO Open. 10. 104987–104987. 1 indexed citations
4.
Niman, Samuel M., AH Partridge, Marco Ruggeri, et al.. (2024). 1814O Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial. Annals of Oncology. 35. S1076–S1076. 3 indexed citations
5.
Rediti, Mattia, David Venet, Marion Maetens, et al.. (2024). Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature Communications. 15(1). 10402–10402. 3 indexed citations
6.
El-Abed, Sarra, et al.. (2024). Nanostructures for cancer therapeutics and diagnostics: Recent advances and future outlook. Radiation Physics and Chemistry. 226. 112295–112295. 3 indexed citations
7.
McArthur, Heather L., Shigehira Saji, Sarra El-Abed, et al.. (2024). Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA/ IMpassion030 phase 3 trial. European Journal of Cancer. 200. 113952–113952. 5 indexed citations
8.
Martins-Branco, Diogo, Marie Kassapian, Véronique Debien, et al.. (2023). The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study. Breast Cancer Research and Treatment. 203(3). 497–509.
9.
Cosimo, Serena Di, Chiara Maura Ciniselli, Sara Pizzamiglio, et al.. (2023). End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. Frontiers in Oncology. 12. 1028825–1028825. 5 indexed citations
10.
11.
Agostinetto, Elisa, Lieveke Ameye, Samuel Martel, et al.. (2022). PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. npj Breast Cancer. 8(1). 87–87. 9 indexed citations
12.
Fernández-Martínez, Aranzazu, Mattia Rediti, Gong Tang, et al.. (2022). Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.. Journal of Clinical Oncology. 40(16_suppl). 509–509. 4 indexed citations
13.
Pizzamiglio, Sara, Giulia Cosentino, Chiara Maura Ciniselli, et al.. (2021). What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Medicine. 11(2). 332–339. 8 indexed citations
14.
Agostinetto, Elisa, Lieveke Ameye, Samuel Martel, et al.. (2021). The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).. Journal of Clinical Oncology. 39(15_suppl). 524–524. 1 indexed citations
15.
Saji, Shigehira, Heather L. McArthur, Michail Ignatiadis, et al.. (2021). ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.. Journal of Clinical Oncology. 39(15_suppl). TPS597–TPS597. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Rodrigo Espinosa Fernández Breakdown of academic impact, for papers by Annette Kolodzie Breakdown of academic impact, for papers by Audrey Gill Breakdown of academic impact, for papers by Vesna Glavicic Breakdown of academic impact, for papers by John Devar Breakdown of academic impact, for papers by Mariane Fontes Breakdown of academic impact, for papers by Sarah Kernaghan Breakdown of academic impact, for papers by A.A. Luczak Breakdown of academic impact, for papers by Brian Chirn Breakdown of academic impact, for papers by Melissa Choz
Rankless by CCL
2026